February 7, 2014
For More Information
As this article has made clear, the HCV treatment landscape is rapidly shifting, and today's realities are quickly giving way to tomorrow's developments. Keep yourself informed by checking in with quality resources for health care providers.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Which Hepatitis C Treatment to Start in 2016|
|This Week in HIV Research: Antibody Suppresses HIV; Investigational Drug BMS-986001; and Quality of Care on Mortality|
|This Week in HIV Research: Tenofovir Resistance Alarmingly Common; Ongoing HIV Replication Replenishes Reservoirs; and More|
|This Week in HIV Research: Reasons for Skipping Meds; Tenofovir Monotherapy PrEP Failures; and Increasing HIV Test Acceptance|
|High Liver Enzymes Signal Serious Disease in HIV-Positive Individuals Without Hepatitis|
|What Can We Learn From HIV-Positive Patients Who Control the Virus After Stopping Treatment?|